These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38662154)

  • 1. Economic Considerations of Cardiovascular Implantable Electronic Devices for The Treatment of Heart Failure.
    Elsner C; Bettin S; Tilz R; Häckl D
    Curr Heart Fail Rep; 2024 Jun; 21(3):186-193. PubMed ID: 38662154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
    Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
    Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remote Monitoring of Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy and Permanent Pacemakers: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2018; 18(7):1-199. PubMed ID: 30443279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
    Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
    Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
    Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of extending device longevity on the long-term costs of implantable cardioverter-defibrillator therapy: a modelling study with a 15-year time horizon.
    Boriani G; Braunschweig F; Deharo JC; Leyva F; Lubinski A; Lazzaro C
    Europace; 2013 Oct; 15(10):1453-62. PubMed ID: 23696624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure.
    Tomini F; Prinzen F; van Asselt AD
    Eur J Health Econ; 2016 Dec; 17(9):1159-1172. PubMed ID: 26728985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimisation of cardiac resynchronisation therapy device selection guided by cardiac magnetic resonance imaging: Cost-effectiveness analysis.
    Crespo C; Linhart M; Acosta J; Soto-Iglesias D; Martínez M; Jáuregui B; Mira Á; Restovic G; Sagarra J; Auricchio A; Fahn B; Boltyenkov A; Lasalvia L; Sampietro-Colom L; Berruezo A
    Eur J Prev Cardiol; 2020 Apr; 27(6):622-632. PubMed ID: 31487998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry.
    Behar JM; Chin HM; Fearn S; Ormerod JO; Gamble J; Foley PW; Bostock J; Claridge S; Jackson T; Sohal M; Antoniadis AP; Razavi R; Betts TR; Herring N; Rinaldi CA
    JACC Clin Electrophysiol; 2017 Feb; 3(2):107-116. PubMed ID: 28280785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic impact of battery longevity in implantable cardioverter-defibrillators for cardiac resynchronization therapy: the hospital and healthcare system perspectives.
    Landolina M; Morani G; Curnis A; Vado A; D'Onofrio A; Bianchi V; Stabile G; Crosato M; Petracci B; Ceriotti C; Bontempi L; Morosato M; Ballari GP; Gasparini M
    Europace; 2017 Aug; 19(8):1349-1356. PubMed ID: 27702861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Cost-Effectiveness of Telemonitoring Patients With Cardiac Implantable Electronic Devices: Systematic Review.
    Raes S; Prezzi A; Willems R; Heidbuchel H; Annemans L
    J Med Internet Res; 2024 Apr; 26():e47616. PubMed ID: 38640471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
    Shah D; Lu X; Paly VF; Tsintzos SI; May DM
    J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
    [No Abstract]   [Full Text] [Related]  

  • 17. Biventricular pacing (cardiac resynchronization therapy): an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(13):1-60. PubMed ID: 23074464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: the perspective of a middle-income country's public health system.
    Bertoldi EG; Rohde LE; Zimerman LI; Pimentel M; Polanczyk CA
    Int J Cardiol; 2013 Mar; 163(3):309-315. PubMed ID: 21704396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation and reimbursement of remote monitoring for cardiac implantable electronic devices in Europe: a survey from the health economics committee of the European Heart Rhythm Association.
    Mairesse GH; Braunschweig F; Klersy K; Cowie MR; Leyva F
    Europace; 2015 May; 17(5):814-8. PubMed ID: 25713012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a risk-stratified approach to cardiac resynchronisation therapy defibrillators (high versus low) at the time of generator change.
    Claridge S; Sebag FA; Fearn S; Behar JM; Porter B; Jackson T; Sieniewicz B; Gould J; Webb J; Chen Z; O'Neill M; Gill J; Leclercq C; Rinaldi CA
    Heart; 2018 Mar; 104(5):416-422. PubMed ID: 28970277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.